SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemiaConstanze Schneider, Jindřich Činátl, Lena Stegmann et al.|Nature Medicine|2016Cited by 185
Botanical drugs and supplements affecting the immune response in the time of <scp>COVID</scp>‐19: Implications for research and clinical practiceThomas Brendler, Elizabeth M. Williamson, Ahmed Al‐Harrasi et al.|Phytotherapy Research|2020Cited by 106
Precision targeting of rhabdomyosarcoma by combining primary CAR NK cells and radiotherapyLisa Marie Reindl, Evelyn Ullrich, Lida Jalili et al.|Journal for ImmunoTherapy of Cancer|2025Cited by 8
Enzastaurin inhibits ABCB1-mediated drug efflux independently of effects on protein kinase C signalling and the cellular p53 statusMartin Michaelis, Jindřich Činátl|European Journal of Cancer|2016Cited by 0